Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma

A patient with advanced and chemotherapy-refractory nodal marginal zone B-c ell lymphoma was given a course of chimeric CD20 monoclonal antibody Rituxi mab. Partial response was observed without any major toxicities. Retreatmen t with Rituximab for disease progression six months after the first course led to partial remission. Adjuvant radiotherapy was given for the residual disease and, currently, patient's disease remains stable eight months after the second course of Rituximab, This case demonstrates the therapeutic eff icacy and feasibility of retreatment with Rituximab for relapsed or refract ory low grade lymphoma.